09:53 AM EST - DiagnoCure Inc. : said it has signed an exclusive agreement with a new partner, Lab21, a provider of diagnostic products and services, for the promotion, marketing and selling of its Previstage GCC Colorectal Cancer Staging Test in the United Kingdom and Ireland. Lab21 said will offer the Previstage GCC test as part of its oncology testing services, and patient samples will be processed in DiagnoCure's U.S. clinical laboratory. Terms of the agreement were not disclosed, the company said. DiagnoCure Inc.
shares T.CUR are trading up $0.08 at $1.29.
